{
  "docId": "019de513-bbaf-7632-8c51-2e65d00dc762",
  "docSlug": "d61504792622527e2ff1c803565a1f5e",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 42 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 42,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de513-bbaf-7632-8c51-2e65d00dc762/26",
  "deckHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762",
  "deckJsonHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762.json",
  "deckAnchorHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.046,
        "w": 0.615,
        "x": 0.158,
        "y": 0.929
      },
      "kind": "source-note",
      "text": "1. See slide 1 for further information on forward-looking statements.\n2. In 2019, the Company acquired an exclusive license from Novaliq GmbH for the commercialization and development of NOV03 in the United States and Canada.\n3. Exclusive licensing agreement with STADA Arneimittel AG and Xbrane Biopharma AB for U.S. and Canada.\n4. Exclusive licensing agreement with Eyenovia, Inc. for U.S. and Canada.\n5. Abbreviated biologics license application..",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a096d115-cf8f-45af-b969-ce84ee390706",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.383,
        "w": 0.87,
        "x": 0.045,
        "y": 0.259
      },
      "kind": "table",
      "text": "Ophthalmic Pharmaceuticals\nProduct\nNOV03² (dry eye disease associated with meibomian gland dysfunction)\nBiosimilar candidate for Lucentis (ranibizumab)³\nMicrodose formulation of atropine ophthalmic solution (reduction of pediatric myopia progression in children ages 3-12)4\nStatus\nSubmitted NDA to FDA in June 2022\nXbrane withdrew aBLA⁵ after receiving feedback from FDA that supplemental information would be required\nUpcoming Milestone\nNDA filing acceptance by FDA expected 3Q22\nResubmission target date expected by end 2022\nClinical trial enrollment completion is delayed from 4Q22 to 1Q23 due to clinical trial material availability",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b84ae22-c680-4f12-9bba-a311748372d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.028,
        "w": 0.429,
        "x": 0.045,
        "y": 0.08
      },
      "kind": "title",
      "text": "Pipeline and Upcoming Milestones¹",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90ae2937-2b5a-4c13-b90d-894e1b383f04",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}